All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Anthracycline-Induced the Left Ventricular Dysfunction in Acute Myeloid Leukemia: A Comprehensive Assessment

Jeffrey Sumith*

Department of Oncology, St. Jude Children's Research Hospital, Memphis , United States of America

*Corresponding Author:
Jeffrey Sumith
Department of Oncology, St. Jude Children's Research Hospital, Memphis , United States of America

Received: 01-Mar-2024, Manuscript No. RCT-24- 129262; Editor assigned: 04-Mar-2023, PreQC No. RCT-24- 129262 (PQ); Reviewed: 18-Mar-2024, QC No. RCT-24- 129262; Revised: 25-Mar-2024, Manuscript No. RCT- 24-129262 (R); Published: 01-Apr-2024, DOI: 10.4172/Rep Cancer Treat.8.1.002. 

Citation: Espejo C. Anthracycline-Induced the Left Ventricular Dysfunction in Acute Myeloid Leukemia: A Comprehensive Assessment. RRJ Cancer and Treatment. 2024; 8: 002.

Copyright: © 2024 Sumith J. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Reports in Cancer and Treatment


Anthracycline-Induced Left ventricular Dysfunction (A-ILD) poses a notable concern in the treatment landscape of Acute Myeloid Leukemia (AML) patients undergoing anthracycline-containing induction chemotherapy. Despite its clinical significance, a comprehensive understanding of A-ILD incidence and predictors in this patient population remains elusive. Incidence of A-ILD in AML patients recent studies have begun to unravel the prevalence of A-ILD in AML patients undergoing anthracycline-containing induction chemotherapy. One such study, conducted at the Dana-Farber Cancer Institute over the period from 2014 to 2022, examined 419 consecutive adult AML patients meeting inclusion criteria for pre- and post-chemotherapy echocardiograms and pre-treatment LVEF>50%. This study revealed that out of the cohort, 8% developed A-ILD post-induction, highlighting the notable risk associated with anthracycline exposure in this population. Notably, a subset of patients (1%) became ineligible for allogeneic stem cell transplantation due to A-ILD, underlining its clinical significance in treatment decision-making.

Predictors of A-ILD

Identifying predictors of A-ILD is crucial for risk stratification and tailored patient management. The study at the Dana-Farber Cancer Institute provided insights into potential predictors of A-ILD in AML patients. Surprisingly, baseline cardiovascular comorbidities, including hypertension, diabetes mellitus, hyperlipidemia, smoking, and coronary artery disease, did not emerge as significant predictors of post-induction A-ILD.

This finding challenges conventional assumptions regarding the role of cardiovascular risk factors in A-ILD development. However, the presence of a JAK2 mutation, identified through comprehensive next-generation sequencing, was associated with an increased risk of A-ILD in multivariable analysis. This novel finding underscores the importance of exploring molecular predictors of A-ILD beyond traditional cardiovascular risk factors.

Clinical implications and future directions

The elucidation of A-ILD incidence and predictors holds significant clinical implications for the management of AML patients undergoing anthracycline-containing induction chemotherapy. Firstly, clinicians should maintain a heightened awareness of the potential risk of A-ILD in this patient population, particularly in those harboring JAK2 mutations. Incorporating routine monitoring of cardiac function, including pre- and post-chemotherapy echocardiography, is paramount for early detection and management of A-ILD. Additionally, future research endeavors should aim to validate and expand upon the identified predictors of A-ILD, including molecular markers such as JAK2 mutations. Understanding the mechanistic underpinnings of A-ILD, particularly in the context of specific genetic mutations, may pave the way for targeted interventions aimed at mitigating A-ILD risk and improving treatment outcomes in AML patients.

Challenges and considerations

While recent studies have provided valuable insights into A-ILD in AML patients, several challenges and considerations warrant attention. Firstly, the retrospective nature of many studies limits the ability to establish causality between potential predictors and A-ILD occurrence. Prospective, longitudinal studies are needed to validate findings and elucidate temporal relationships between predictors and A-ILD development. Moreover, the complexity of A-ILD etiology, involving multifactorial interactions between anthracycline exposure, genetic predisposition, and cardiovascular health, underscores the need for a multidisciplinary approach to patient care. Collaboration between oncologists, cardiologists, and molecular biologists is essential for advancing our understanding of A-ILD and developing effective preventive strategies and treatments.

The recent research efforts have brought the incidence and predictors of anthracycline-induced left ventricular dysfunction (A-ILD) in acute myeloid leukemia (AML) patients undergoing induction chemotherapy. While challenges persist, including the need for prospective validation and mechanistic elucidation, these findings represent a significant step forward in our understanding of A-ILD in AML. By incorporating routine cardiac monitoring and exploring novel molecular predictors, clinicians and researchers can strive to mitigate A-ILD risk and improve outcomes for AML patients undergoing anthracycline containing induction chemotherapy